(Q39112227)

9 September 2017

title

A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer (English)

1 reference

9 September 2017

1 reference

10

1 reference

9 September 2017

8

F André

0 references

Sophie Postel-Vinay

1

object named as

S Postel-Vinay

0 references

Jean-Charles Soria

9

object named as

J-C Soria

0 references

Alan Ashworth

11

object named as

A Ashworth

1 reference

9 September 2017

S Postel-Vinay

1

1 reference

9 September 2017

I Bajrami

2

1 reference

9 September 2017

L Friboulet

3

1 reference

9 September 2017

R Elliott

4

1 reference

9 September 2017

Y Fontebasso

5

1 reference

9 September 2017

N Dorvault

6

1 reference

9 September 2017

K A Olaussen

7

1 reference

9 September 2017

F André

8

1 reference

9 September 2017

J-C Soria

9

1 reference

9 September 2017

language of work or name

English

0 references

publication date

12 August 2013

1 reference

9 September 2017

1 reference

9 September 2017

volume

32

1 reference

9 September 2017

issue

47

1 reference

9 September 2017

page(s)

5377-5387

1 reference

9 September 2017

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Biomarker studies: a call for a comprehensive biomarker study registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

DNA repair dysregulation from cancer driver to therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Regulation of endonuclease activity in human nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Interstrand crosslink repair: can XPF-ERCC1 be let off the hook?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

ERCC1 isoform expression and DNA repair in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

ERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Exploring biomarkers in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

ERCC1: impact in multimodality treatment of upper gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Synthetic lethal approaches to breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Mutational analysis of the human nucleotide excision repair gene ERCC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The impacts of ERCC1 gene exon VIII alternative splicing on cisplatin-resistance in ovarian cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The structure-specific endonuclease Ercc1-Xpf is required for targeted gene replacement in embryonic stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA: STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

RNA interference screening demystified

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.311

31 March 2020

Identifiers

DOI

10.1038/ONC.2013.311

1 reference

9 September 2017

1 reference